Venclexta 50mg Tablet contains the active ingredient Venetoclax. Venclexta 50mg Tablet is an antineoplastic drug that belongs to the class of BCL-2 inhibitors. It is used to treat adults with certain types of blood cancers, including chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). Specifically, it is used in CLL with a 17p deletion and in AML in patients who cannot undergo intensive chemotherapy. Additionally, it can be used in combination with other medications to treat certain types of non-Hodgkin lymphoma. Venclexta 50mg Tablet works by inhibiting the BCL-2 protein, which helps promote cancer cell death. This action restores the process of apoptosis (programmed cell death) by binding to BCL-2, displacing pro-apoptotic proteins, and initiating mitochondrial outer membrane permeabilisation, which triggers cell death. Do not take Venclexta 50mg Tablet if you are allergic to Venetoclax or any of the other ingredients in the medication. Before starting treatment, inform your doctor if you have kidney problems, a history of infections, or any blood-related disorders like low white blood cell count or low platelet count. Ensure that your physician is aware of any past history of Tumor Lysis Syndrome (TLS) or if you are pregnant or planning to become pregnant, as Venclexta may harm the fetus. Venclexta 50mg Tablet should not be used in children or adolescents under the age of 18.